Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lise Aagaard

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Ugeskrift for Laeger|February 14, 2013
[Knowledge creation about adverse drug reactions in the paediatric population]Lise Aagaard
International Journal of Clinical Pharmacy|August 14, 2020
Marketing of healthcare services in Denmark: the concept of misleading advertisingLise Aagaard
International Journal of Clinical Pharmacy|May 4, 2018
Off-label and unlicensed prescribing in Europe: implications for patients' informed consent and liabilityLise Aagaard, Kent Kristensen
British Journal of Clinical Pharmacology|January 19, 2011
Prescribing of medicines in the Danish paediatric population outwith the licensed age group: characteristics of adverse drug reactionsLise Aagaard, Ebba Holme Hansen
BMC Clinical Pharmacology|March 4, 2009
Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDsLise Aagaard, Ebba Holme Hansen
BMC Research Notes|June 25, 2010
Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish Medicines Agency over a decadeLise Aagaard, Ebba H Hansen
International Journal of Clinical Pharmacy|October 8, 2014
Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011Lise Aagaard, Ebba Holme Hansen
Current Drug Safety|August 7, 2013
Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United StatesLise Aagaard, Ebba Holme Hansen
Neuropsychiatric Disease and Treatment|January 17, 2012
The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studiesLise Aagaard, Ebba Holme Hansen
Current Drug Safety|August 6, 2013
Adverse Drug Reaction Labeling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for oral Formulations in Australia, Denmark and the United StatesLise Aagaard, Ebba Holme Hansen
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Ugeskrift for Laeger|February 14, 2013
[Knowledge creation about adverse drug reactions in the paediatric population]Lise Aagaard
International Journal of Clinical Pharmacy|August 14, 2020
Marketing of healthcare services in Denmark: the concept of misleading advertisingLise Aagaard
International Journal of Clinical Pharmacy|May 4, 2018
Off-label and unlicensed prescribing in Europe: implications for patients' informed consent and liabilityLise Aagaard, Kent Kristensen
British Journal of Clinical Pharmacology|January 19, 2011
Prescribing of medicines in the Danish paediatric population outwith the licensed age group: characteristics of adverse drug reactionsLise Aagaard, Ebba Holme Hansen
BMC Clinical Pharmacology|March 4, 2009
Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDsLise Aagaard, Ebba Holme Hansen
BMC Research Notes|June 25, 2010
Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish Medicines Agency over a decadeLise Aagaard, Ebba H Hansen
International Journal of Clinical Pharmacy|October 8, 2014
Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011Lise Aagaard, Ebba Holme Hansen
Current Drug Safety|August 7, 2013
Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United StatesLise Aagaard, Ebba Holme Hansen
Neuropsychiatric Disease and Treatment|January 17, 2012
The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studiesLise Aagaard, Ebba Holme Hansen
Current Drug Safety|August 6, 2013
Adverse Drug Reaction Labeling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for oral Formulations in Australia, Denmark and the United StatesLise Aagaard, Ebba Holme Hansen
Pageof 6